Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM +1.66%100 ROC (Joel Greenblatt) % is 132.29% as of Dec. 2025, which is 8% above its 10-year median of 122.25. GuruFocus rates OCSE:CHEMM with a GF Score™ of 100/100 and a GF Value™ of kr551.78 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 840 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 97.86% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ChemoMetec AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 132.29%.
The historical rank and industry rank for ChemoMetec AS's ROC (Joel Greenblatt) % or its related term are showing as below:
OCSE:CHEMM'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.23 Med: 122.25 Max: 321.08
Current: 119.3
During the past 13 years, ChemoMetec AS's highest ROC (Joel Greenblatt) % was 321.08%. The lowest was 24.23%. And the median was 122.25%.
OCSE:CHEMM's ROC (Joel Greenblatt) % is ranked better than 97.86% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs OCSE:CHEMM: 119.30
ChemoMetec AS's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -6.00% per year.
ChemoMetec AS (OCSE:CHEMM) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
ChemoMetec AS ROC (Joel Greenblatt) % Related Terms
ChemoMetec AS ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, ChemoMetec AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 132.29% mean?
ChemoMetec AS (OCSE:CHEMM) has a ROC (Joel Greenblatt) % of 132.29% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ChemoMetec AS and its competitors. This is near median its historical median of 122.25. Over the past decade, ChemoMetec AS's ROC (Joel Greenblatt) % has ranged from 24.23 to 321.08. According to the industry distribution chart, ChemoMetec AS ranks #18 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 2.1%.
Is ChemoMetec AS's ROC (Joel Greenblatt) % too high?
ChemoMetec AS's current ROC (Joel Greenblatt) % of 132.29% is near median its 10-year median of 122.25. Over the past 10 years, this metric has ranged from a low of 24.23 to a high of 321.08. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. ChemoMetec AS's value of 132.29% is 3091.6% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #18 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ChemoMetec AS has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #18 out of 840 companies for ROC (Joel Greenblatt) %. This places ChemoMetec AS in the top 2% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.15. ChemoMetec AS's value of 132.29% is 3091.6% above this benchmark. Historically, ChemoMetec AS's own ROC (Joel Greenblatt) % has ranged from 24.23 to 321.08 over the past decade. While the company's 10-year median is 122.25 vs. the industry median of 4.15, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current ROC (Joel Greenblatt) % of 132.29% is 3091.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current ROC (Joel Greenblatt) % is 132.29%, which is near median its own 10-year median of 122.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr551.78, compared to a current price of kr417.40 — trading 24.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 132.29%, which is near median its 10-year median of 122.25 and 3091.6% above the Medical Devices & Instruments industry median of 4.15. ChemoMetec AS's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current ROC (Joel Greenblatt) % is 132.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr417.40 is trading 24.4% below its estimated GF Value™ of kr551.78.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
ROC (Joel Greenblatt) %: 132.29% (near median its 10-year median of 122.25)
GF Value™: kr551.78 vs. price of kr417.40 (24.4% below fair value)
Industry Position: 3091.6% above the Medical Devices & Instruments median (#18 of 840)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
100GF Score
Get the complete analysis for OCSE:CHEMM
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
